Press Releases

Date	Title	Format
July 28, 2023	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy	PDF Version
June 17, 2023	Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress	PDF Version
June 12, 2023	Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress	PDF Version
June 12, 2023	Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG	PDF Version
May 16, 2023	Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease	PDF Version
May 9, 2023	Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates	PDF Version
May 5, 2023	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
May 5, 2023	Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress	PDF Version
April 27, 2023	Chinook Therapeutics to Present at Upcoming Investor Conferences	PDF Version
April 13, 2023	Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors	PDF Version

Investors